Lv2
170 积分 2023-04-10 加入
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
3个月前
已完结
Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis. Proceedings of a consensus conference. Lyon, France, 3-7 November 1997
1年前
已关闭
Gastric Neuroendocrine Tumors in a 2-Year Oncogenicity Study With CD-1 Mice
1年前
已完结
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor
1年前
已完结
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
1年前
已完结
First-in-class Dual Inhibitors of MASTL and Aurora A Kinase: Discovery of Selective Cyclohexa[b]thiophenes with Potent Anticancer Activity
1年前
已完结
皖公网安备34019202002308
